Parse Biosciences is building scalable single-cell sequencing platforms for researchers. One of the latest advances in genomics is single-cell technologies, however, most use microfluidic instruments that limit cell sizes and number and produce high multiplets. Parse has developed the Parse Evercode single-cell technology that enables all scales of experiments without the limitation of today’s microfluidics. Evercode offers single-cell profiling from 10,000 to 1 million cells in a single experiment, flexibility with sample scheduling and unmatched sensitivity.
Evercode combinatorial barcoding technology eliminates the need for expensive hardware, making single cell insights accessible to biological researchers in any lab.